Linagliptin Medochemie

Linagliptin, the active ingredient in Linagliptin Medochemie, is a DPP-4 inhibitor presented as a tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus. GNH USA supplies Linagliptin Medochemie as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor indicated for the management of type 2 diabetes mellitus, either alone or in combination with other antidiabetic agents. - Type 2 diabetes mellitus (monotherapy): improves glycaemic control by enhancing insulin secretion and reducing glucagon release. - Type 2 diabetes mellitus (combined with metformin): provides additional glucose‑lowering effect when metformin alone is insufficient. - Type 2 diabetes mellitus (renal impairment): offers effective glycaemic control without the need for dose adjustment in patients with mild to moderate renal dysfunction.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Dizziness: occasional light‑headedness. - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Upper respiratory infection: cough or sore throat. - Back pain: occasional musculoskeletal discomfort.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: angioedema, anaphylaxis, or rash. - Hepatic injury: jaundice or abnormal liver function tests. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hypoglycaemia (when combined with sulfonylureas or insulin): dizziness, sweating, confusion. - Acute renal failure (rare): reduced urine output and fluid overload.

Linagliptin should be used with caution in the following situations: - Renal impairment: monitor renal function regularly, especially in patients with chronic kidney disease. - Hepatic impairment: assess liver enzymes before initiating therapy. - Concomitant sulfonylureas or insulin: risk of hypoglycaemia, adjust dose as needed. - Cardiovascular disease: observe for any worsening of heart failure symptoms. - Pregnancy and breastfeeding: safety not established, avoid unless clearly needed. - Storage: Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Linagliptin may interact with several medicines that affect glucose levels or drug metabolism. Major Interactions (Avoid): - Sulfonylureas: increased risk of hypoglycaemia; dose adjustment required. - Insulin: additive glucose‑lowering effect; monitor blood sugar closely. - Strong CYP3A4 inducers (e.g., rifampin): may reduce linagliptin exposure and efficacy. Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin plasma concentrations. - Diuretics and ACE inhibitors: potential impact on renal function; monitor electrolytes and renal markers. - NSAIDs: may affect renal clearance; assess renal function periodically.